2017
DOI: 10.1016/j.bios.2017.05.042
|View full text |Cite
|
Sign up to set email alerts
|

Electrochemical sensors for identifying pyocyanin production in clinical Pseudomonas aeruginosa isolates

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1
1

Citation Types

1
64
0

Year Published

2018
2018
2024
2024

Publication Types

Select...
8

Relationship

0
8

Authors

Journals

citations
Cited by 63 publications
(65 citation statements)
references
References 32 publications
1
64
0
Order By: Relevance
“…The wavelength of 600 nm was chosen for OD, because 600 nm does not interfere with the absorbance of GFP, which absorbs at 475 nm. Therefore, relative errors are eliminated by avoiding interfering wavelengths between bacteria and fluorescent proteins or other fluorescent molecules that are present in PA, including pyocyanine and pyoverdine [53,54]. This point also strengthens the argument regarding why additional methods for bacterial quantification, such as fluorescence spectroscopy using EGFP, are desired, as they avoid the overlap of absorbing wavelengths.…”
Section: Fluorescence Spectroscopy As a Tool To Quantify The Planktonmentioning
confidence: 58%
“…The wavelength of 600 nm was chosen for OD, because 600 nm does not interfere with the absorbance of GFP, which absorbs at 475 nm. Therefore, relative errors are eliminated by avoiding interfering wavelengths between bacteria and fluorescent proteins or other fluorescent molecules that are present in PA, including pyocyanine and pyoverdine [53,54]. This point also strengthens the argument regarding why additional methods for bacterial quantification, such as fluorescence spectroscopy using EGFP, are desired, as they avoid the overlap of absorbing wavelengths.…”
Section: Fluorescence Spectroscopy As a Tool To Quantify The Planktonmentioning
confidence: 58%
“…An actual electrochemical detection of pyocyanin in clinical isolates was conducted by Sismaet et al on 94 different isolates from patients with hospital-acquired infections or patients with cystic fibrosis. The results proved that all the isolates produced pyocyanin [ 42 ]. This is an important finding for the direct identification of PA in clinical samples, as nonproducing PA isolates would lead to false negatives when using pyocyanin as a biomarker for PA.…”
Section: Pyocyanin Detection In Clinical Isolatesmentioning
confidence: 97%
“…To successfully apply the electrochemical detection of pyocyanin for PA identification in clinical samples, several studies measured human fluids spiked with pyocyanin [ 31 , 32 , 48 ]. The investigated human fluids covered urine, blood, bronchial lavage, sputum, saliva and hypertonic saline for laryngeal aspirate suctions as well as simulated wound fluid and artificial sputum medium [ 25 , 33 , 37 , 42 , 43 ]. PA is a urinary tract pathogen, which makes urine an obvious body fluid to develop pyocyanin detection in.…”
Section: Towards Clinical Applicationsmentioning
confidence: 99%
“…Indeed, this virulence factor is uniquely synthesized by PA as it is the only bacterial species carrying the two specific protein‐encoding genes (PhzM, PhzS) necessary to form PYO. [ 62 ] PYO has been proven to exist in all nosocomial strains of PA within a clinically viable concentration of 2–100 µ m , though concentrations of up to 130 µ m have been reported in instances of pulmonary infection, namely bronchiectasis. [ 20b,63 ] Consequently, PYO is of great interest for the detection of PA. PYO presents an oxidized and reduced forms following the gain or loss of electrons at the standard redox potential of −247 mV versus Ag/AgCl (Figure 4C).…”
Section: Electrochemical Detection Of Pamentioning
confidence: 99%